All News

acr_session2.jpeg

ACR 2024 - Day 3 Report

d Jack Cush, MD

Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.

Read Article
PMR spotlight

JAKs and Other Drugs in PMR

d Richard Conway, MBBChBAO, PhD

This has been an interesting ACR meeting in terms of PMR updates. I would argue that we are still far too wedded to glucocorticoids only in the management of PMR. Yes, some patients will do fine with just glucocorticoids but we persist far too long with a glucocorticoid only strategy in others who clearly need an alternative as glucocorticoid adverse events multiply.

Read Article
Convention1.jpg

#ACR 2024 BEST Abstracts from Day 3

d Jack Cush, MD

Lots of lupus research and the New ACR Guidelines on Lupus Nephritis management were presented today. These and other highlights as featured on our Twitter (X) feed from ACR24 in Washington, DC.

Read Article
JAK-pot! How fast do DMARDs work? Dr. Mike Putman interviews Dr. Kim Lauper about abstract 0501, How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients… https://t.co/GO9EwyrVpV https://t.co/lELE5SJW5i
Dr. John Cush RheumNow ( View Tweet)
PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Dr. Sheila Reyes reports on abstract 0571, Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study, presented at #ACR24.… https://t.co/EGlCap6pEw

Dr. John Cush RheumNow ( View Tweet)

@DrLisaCS distills the challenges of MCTD 👇 🔵Clinical phenotyping key to improve patient outcomes @jhrheumatology @RheumNow #acr24 https://t.co/APfXPwxvfE

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

Continuing or Stopping Low Dose Glucocorticoids in GPA Dr. Mike Putman reports about plenary session abstract 0774 (the TAPIR study) about how and when patients can stop steroids in GPA. #ACR24 https://t.co/OWqN0jmkc1 https://t.co/foOaVRtGiV

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

RheumNow Day 3 Recap: ACR Convergence 2024 Highlights https://t.co/jFIATPKlp7

Links:

Dr. John Cush RheumNow ( View Tweet)

I've shared some thoughts on @RheumNow on methotrexate, tocilizumab, and baricitinib in PMR based on #ACR24 https://t.co/WXiW1nLN4k

Links:

Richard Conway RichardPAConway ( View Tweet)

TNFis preventing cancer compared to placebo, and JAKi being neutral to placebo and maybe preventing haem cancers also. #ACR24 abstract 0989 was certainly provocative. I've shared my thoughts on @RheumNow https://t.co/yQFoUGifEN

Links:

Richard Conway RichardPAConway ( View Tweet)

Pathophysiological pathways in neuropsychiatric SLE. 2 components: -Ischaemic -Inflammatory Zahi Touma @RheumNow #ACR24 https://t.co/wwlSSSpOIU

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Great project by @kekuchinad to evaluate how PFTs bias our assessment and contribute to disparities @CaoilfhionnMD @jhrheumatology @BayviewMedicine @RheumNow #ACR24 https://t.co/b5pAn3e9AR https://t.co/opzWrZ1NH5

Links:

Eric Dein ericdeinmd ( View Tweet)

Potential Impact of Weight Loss Drugs in Rheumatic Diseases Dr. Arthur Kavanaugh highlights a session regarding weight loss and improvement in disease outcomes, specific weight loss drugs (SGL-2 and GLP-1), along with downsides when patients stop these medications. Reporting… https://t.co/Ilu2FXK2xi https://t.co/7CKSnfuey4
Dr. John Cush RheumNow ( View Tweet)
Yang et al. Cranial vessel wall MRI in GCA. Quantitated with PEG score. PEG score ocular GCA>non-ocular GCA>non-GCA. Decreases with treatment. @RheumNow #ACR24 Abstr#2650 https://t.co/e26urOpb7V https://t.co/eekQbzmKYm

Links:

Richard Conway RichardPAConway ( View Tweet)
A#2651 Vasculitis w VEXAS 81 men, median age 67 - 27% had evid of vasculitis, variable size vessel 22% SVV- 17/18 cutaneous, one peritubular capillaritis on renal bx 2.5% MVV (2 cutan), LVV (2 carotid thickening, 1 had +TA bx), ANCA+ @RheumNow #ACR24 https://t.co/puablIBLCP

Links:

Eric Dein ericdeinmd ( View Tweet)
What factors are assoc with uptake of newer meds in RA? ➡️Incr use of b/tsDMARDs over 10yrs ➡️Use of newer drugs lower in older ppl, socioeconomic deprived & Asian/Black ppl Could this indicate disparities in access to meds? How can we best address this? Ab2608 #ACR24 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

Subsets of lupus arthritis. Kenneth Kalunian @RheumNow #ACR24 https://t.co/ZmHui126zr

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP

Links:

Richard Conway RichardPAConway ( View Tweet)
How often do you ask about #fatigue, #depression & #anxiety in pts with RMDs? Study of >1000 pts found anxiety symptoms in 1/3 pts and significant association between fatigue & anxiety and depression Highlights importance of regular review of MH symptoms Ab2657 #ACR24 @RheumNow https://t.co/0zMOMybrCI

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×